{"created":"2024-10-30T10:06:49.657656+00:00","id":2007962,"links":{},"metadata":{"_buckets":{"deposit":"375c3331-346b-4ad4-a325-d080f7ba7e19"},"_deposit":{"created_by":7,"id":"2007962","owners":[7],"pid":{"revision_id":0,"type":"depid","value":"2007962"},"status":"published"},"_oai":{"id":"oai:tokushima-u.repo.nii.ac.jp:02007962","sets":["1713853213384:1713853295607"]},"author_link":["1539"],"control_number":"2007962","item_10001_alternative_title_1":{"attribute_name":"タイトル別表記","attribute_value_mlt":[{"subitem_alternative_title":"Brodalumab in patients with GPP and PsE","subitem_alternative_title_language":"en"}]},"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-04-23","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"751","bibliographicPageStart":"741","bibliographicVolumeNumber":"176","bibliographic_titles":[{"bibliographic_title":"British Journal of Dermatology","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background\nA T‐helper (Th) cell subset Th17 preferentially produces interleukin (IL)‐17 and plays a pivotal role in the pathogenesis of psoriasis. However, the pathological roles of IL‐17 cascades in generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE) have not been well established.\nObjectives\nTo evaluate the efficacy and safety of brodalumab, a human immunoglobulin G2 monoclonal antibody against human IL ‐17‐receptor A (IL‐17RA), in Japanese patients with GPP and PsE.\nMethods\nThis was an open‐label, multicentre, long‐term phase III study in Japanese patients with rare and severe types of psoriasis. Patients received brodalumab 140 mg at day 1 and weeks 1 and 2, and then every 2 weeks until week 52. The primary endpoint was the Clinical Global Impression of Improvement (CGI). Safety evaluations included treatment‐emergent adverse events (AEs) and changes in laboratory parameters.\nResults\nA total of 12 patients with GPP and 18 with PsE were enrolled. Ten patients with GPP and 16 with PsE completed the study. At week 52 (last observation carried forward), CGI remission or improvement was achieved in 11 patients with GPP and 18 with PsE. The most commonly reported AE was nasopharyngitis (33·3%). Five serious AE s occurred during the study. However, none was considered treatment‐related.\nConclusions\nBrodalumab significantly improved the symptoms of patients with GPP and PsE throughout the 52 weeks, and demonstrated favourable safety profiles without any new safety signals. Inhibition of IL‐17RA‐mediated signalling by brodalumab is expected to be a promising new treatment option for patients with GPP and PsE.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"British Association of Dermatologists","subitem_publisher_language":"en"},{"subitem_publisher":"Wiley & Sons","subitem_publisher_language":"en"}]},"item_10001_rights_15":{"attribute_name":"権利情報","attribute_value_mlt":[{"subitem_rights":"This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.","subitem_rights_language":"en"}]},"item_10001_source_id_9":{"attribute_name":"収録物ID","attribute_value_mlt":[{"subitem_source_identifier":"13652133","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1715043197608":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access"}]},"item_1722929371688":{"attribute_name":"出版社版DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_language":"ja","subitem_relation_name_text":"10.1111/bjd.14702"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1111/bjd.14702","subitem_relation_type_select":"DOI"}}]},"item_1723180141928":{"attribute_name":"EID","attribute_value_mlt":[{"subitem_identifier_type":"URI","subitem_identifier_uri":"342245"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"ヤマサキ","creatorNameLang":"ja"},{"creatorName":"ヤマサキ","creatorNameLang":"ja-Kana"},{"creatorName":"Yamasaki, K.","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"ナカガワ","creatorNameLang":"ja"},{"creatorName":"ナカガワ","creatorNameLang":"ja-Kana"},{"creatorName":"Nakagawa, H.","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"久保, 宜明","creatorNameLang":"ja"},{"creatorName":"クボ, ヨシアキ","creatorNameLang":"ja-Kana"},{"creatorName":"Kubo, Yoshiaki","creatorNameLang":"en"}],"familyNames":[{"familyName":"久保","familyNameLang":"ja"},{"familyName":"クボ","familyNameLang":"ja-Kana"},{"familyName":"Kubo","familyNameLang":"en"}],"givenNames":[{"givenName":"宜明","givenNameLang":"ja"},{"givenName":"ヨシアキ","givenNameLang":"ja-Kana"},{"givenName":"Yoshiaki","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1539","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"60055/profile-ja.html","nameIdentifierScheme":"徳島大学 教育研究者総覧","nameIdentifierURI":"http://pub2.db.tokushima-u.ac.jp/ERD/person/60055/profile-ja.html"},{"nameIdentifier":"10260069","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://nrid.nii.ac.jp/ja/search/?qm=10260069"}]},{"creatorNames":[{"creatorName":"オオタキ","creatorNameLang":"ja"},{"creatorName":"オオタキ","creatorNameLang":"ja-Kana"},{"creatorName":"Ootaki, K.","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2020-09-23"}],"displaytype":"detail","filename":"bjd_176_3_741.pdf","filesize":[{"value":"447 KB"}],"format":"application/pdf","licensetype":"license_5","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://tokushima-u.repo.nii.ac.jp/record/2007962/files/bjd_176_3_741.pdf"},"version_id":"14e380c0-79b2-4213-bcf4-2d79bf994460"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma : results from a 52‐week, open‐label study","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma : results from a 52‐week, open‐label study","subitem_title_language":"en"}]},"item_type_id":"40001","owner":"7","path":["1713853295607"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-09-23"},"publish_date":"2020-09-23","publish_status":"0","recid":"2007962","relation_version_is_last":true,"title":["Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma : results from a 52‐week, open‐label study"],"weko_creator_id":"7","weko_shared_id":-1},"updated":"2025-01-28T07:00:50.213788+00:00"}